GAMIFANT
PeakmAbemapalumab-lzsg
BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
GAMIFANT (emapalumab-lzsg) is interferon gamma antagonists [moa]. First approved in 2018.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GAMIFANT (emapalumab-lzsg) is a monoclonal antibody that blocks interferon gamma, a key cytokine driving pathologic immune activation. It is indicated for primary hemophagocytic lymphohistiocytosis (HLH), a rare, life-threatening hyperinflammatory disorder. The drug works by antagonizing IFN-γ signaling to suppress the cytokine-driven immune cascade.
$0.983MPart D
PeakPeak-stage orphan product with modest Medicare utilization; brand and medical teams are focused on maintaining market access and managed care reimbursement in a rare disease setting.
Mechanism of Action
Interferon gamma Antagonists
Pharmacologic Class:
Interferon gamma Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GAMIFANT offers deep expertise in rare disease commercialization, orphan drug reimbursement, and niche market management. Career growth is constrained by limited patient population and stable lifecycle; emphasis is on access expansion and clinical education rather than new indication launches.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.